SARS-CoV-2阳性就诊者的症状报告与疫苗接种状态——美国增加社区检测、治疗和响应项目,2023年9月至2024年8月
研究利用增加社区检测、治疗和响应(ICATT)平台数据,分析2023年9月21日至2024年8月22日期间6966份首次SARS-CoV-2阳性检测记录,发现接种2023-2024年COVID-19疫苗者报告12种症状的频率持续较低,且报告大多数症状的调整比值比显著更低。
要点
- 接种2023-2024年COVID-19疫苗者报告大多数症状的调整比值比显著更低。
- 近期嗅觉或味觉丧失的调整比值比为0.39(95%CI:0.29-0.53)。
- 肌肉疼痛的调整比值比为0.49(95%CI:0.41-0.59)。
核心结论
- 接种2023-2024年COVID-19疫苗与SARS-CoV-2感染后报告大多数COVID-19症状的比值比显著降低相关,凸显接种推荐COVID-19疫苗以减轻有症状疾病的重要性。
研究设计与样本
- 研究使用增加社区检测、治疗和响应(ICATT)平台数据,纳入2023年9月21日至2024年8月22日期间6966份首次SARS-CoV-2阳性检测记录。
主要发现
- 接种2023-2024年COVID-19疫苗者报告12种症状的频率持续较低。
- 接种者报告大多数症状的调整比值比显著更低,尤其是近期嗅觉或味觉丧失(aOR:0.39;95%CI:0.29-0.53)和肌肉疼痛(aOR:0.49;95%CI:0.41-0.59)。
关键数值与推荐
- 2023年9月12日,美国疾病控制与预防中心免疫实践咨询委员会推荐所有年龄≥6个月者接种2023-2024年COVID-19疫苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On September 12, 2023, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended that all persons aged ≥6 months receive 2023-2024 COVID-19 vaccination. This study examines the relationship between vaccination and COVID-19 symptom frequency, using data from the Increasing Community Access to Testing, Treatment, and Response (ICATT) platform. Among 6966 records of first SARS-CoV-2-positive tests collected from September 21, 2023 through August 22, 2024, individuals who received 2023-2024 COVID-19 vaccination consistently reported lower frequencies of 12 symptoms. The adjusted odds of reporting most symptoms were significantly lower among vaccinated participants, especially recent loss of sense of smell or taste (adjusted odds ratio(aOR): 0.39; 95 %CI: 0.29-0.53) and muscle pain (aOR: 0.49; 95 %CI: 0.41-0.59). These findings indicate that receiving 2023-2024 COVID-19 vaccination was associated with significantly lower odds of reporting most COVID-19 symptoms following SARS-CoV-2 infection, highlighting the importance of receiving recommended COVID-19 vaccination to mitigate symptomatic illness.
引用
- Ciesla AA, Mak J, Godoshian A, et al. Symptom reporting and vaccination status among SARS-CoV-2-positive encounters - Increasing Community Access to Testing, Treatment, and Response program, United States, September 2023-August 2024. Vaccine. 2025. PMID: 40850291. doi:10.1016/j.vaccine.2025.127635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。